<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">8109498</journal-id>
<journal-id journal-id-type="pubmed-jr-id">4636</journal-id>
<journal-id journal-id-type="nlm-ta">J Neuroimmunol</journal-id>
<journal-id journal-id-type="iso-abbrev">J. Neuroimmunol.</journal-id>
<journal-title-group>
<journal-title>Journal of neuroimmunology</journal-title>
</journal-title-group>
<issn pub-type="ppub">0165-5728</issn>
<issn pub-type="epub">1872-8421</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28601278</article-id>
<article-id pub-id-type="pmc">7169431</article-id>
<article-id pub-id-type="doi">10.1016/j.jneuroim.2017.05.017</article-id>
<article-id pub-id-type="manuscript">NIHMS1579765</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Laquinimod has no effects on brain volume or cellular CNS composition
in the F1 3xTg-AD/C3H mouse model of Alzheimer’s disease</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Hussain</surname>
<given-names>Rehana Z.</given-names>
</name>
<xref ref-type="aff" rid="A1">a</xref>
<xref ref-type="author-notes" rid="FN1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Miller-Little</surname>
<given-names>William A.</given-names>
</name>
<xref ref-type="aff" rid="A1">a</xref>
<xref ref-type="author-notes" rid="FN1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lambracht-Washington</surname>
<given-names>Doris</given-names>
</name>
<xref ref-type="aff" rid="A1">a</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Jaramillo</surname>
<given-names>Tom C.</given-names>
</name>
<xref ref-type="aff" rid="A1">a</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Takahashi</surname>
<given-names>Masaya</given-names>
</name>
<xref ref-type="aff" rid="A2">b</xref>
<xref ref-type="aff" rid="A3">c</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhang</surname>
<given-names>Shanrong</given-names>
</name>
<xref ref-type="aff" rid="A3">c</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Fu</surname>
<given-names>Min</given-names>
</name>
<xref ref-type="aff" rid="A1">a</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Cutter</surname>
<given-names>Gary R.</given-names>
</name>
<xref ref-type="aff" rid="A4">d</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hayardeny</surname>
<given-names>Liat</given-names>
</name>
<xref ref-type="aff" rid="A5">e</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Powell</surname>
<given-names>Craig M.</given-names>
</name>
<xref ref-type="aff" rid="A1">a</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rosenberg</surname>
<given-names>Roger N.</given-names>
</name>
<xref ref-type="aff" rid="A1">a</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Stüve</surname>
<given-names>Olaf</given-names>
</name>
<xref ref-type="aff" rid="A1">a</xref>
<xref ref-type="aff" rid="A6">f</xref>
<xref ref-type="aff" rid="A7">g</xref>
<xref ref-type="corresp" rid="CR1">*</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>a</label>Department of Neurology and Neurotherapeutics, the
University of Texas Southwestern Medical Center at Dallas, USA</aff>
<aff id="A2"><label>b</label>Department of Radiology, University of Texas Southwestern
Medical Center at Dallas, USA</aff>
<aff id="A3"><label>c</label>Advanced Imaging Center, University of Texas Southwestern
Medical Center at Dallas, USA</aff>
<aff id="A4"><label>d</label>Department of Biostatistics, University of Alabama at
Birmingham, USA</aff>
<aff id="A5"><label>e</label>Teva Pharmaceuticals, Petah Tikva, Israel</aff>
<aff id="A6"><label>f</label>Department of Neurology, Klinikum rechts der Isar,
Technische Universität München, Germany</aff>
<aff id="A7"><label>g</label>Neurology Section, VA North Texas Health Care System,
Medical Service Dallas, VA Medical Center, USA</aff>
<author-notes>
<fn fn-type="equal" id="FN1">
<label>1</label>
<p id="P1">These authors contributed equally.</p>
</fn>
<corresp id="CR1"><label>*</label>Corresponding author at: Neurology Section, VA
North Texas Health Care System, Medical Service, 4500 South Lancaster Rd.,
Dallas, TX 75216, USA. <email>olaf.stuve@utsouthwestern.edu</email> (O.
Stüve).</corresp>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>27</day>
<month>3</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>26</day>
<month>5</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="ppub">
<day>15</day>
<month>8</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>20</day>
<month>4</month>
<year>2020</year>
</pub-date>
<volume>309</volume>
<fpage>100</fpage>
<lpage>110</lpage>
<!--elocation-id from pubmed: 10.1016/j.jneuroim.2017.05.017-->
<abstract id="ABS1">
<sec id="S1">
<title>Background:</title>
<p id="P2">Laquinimod is an anti-inflammatory agent with good central nervous
system (CNS) bioavailability, and neuroprotective and myelorestorative
properties. A clinical trial in patients with multiple sclerosis
demonstrated that laquinimod significantly reduced loss of brain volume. The
cellular substrate or molecular events underlying that treatment effect are
unknown. In this study, we aimed to explore laquinimod’s potential
effects on brain volume, animal behavior, cellular numbers and composition
of CNS-intrinsic cells and mononuclear cells within the CNS, amyloid beta
(Aβ) accumulation and tau phosphorylation in the F1 3xTg-AD/C3H mouse
model of Alzheimer’s disease.</p>
</sec>
<sec id="S2">
<title>Methods:</title>
<p id="P3">Utilizing a dose response study design, four months old F1
3xTg-AD/C3H mice were treated for 10 months between ages 4 and 14 months
with laquinimod (5, 10, or 25 mg/kg), or PBS administered by oral gavage.
Brain volumes were measured in a 7 Tesla magnetic resonance imager (MRI) at
ages 4 and 14 months. Behavioral testing included locomotor and rearing
activity and the Morris water maze task. Cell numbers and immunophenotypes
were assessed by multiparameter flow cytometry. Aβ deposition and tau
phosphorylation were determined by immunohistochemistry.</p>
</sec>
<sec id="S3">
<title>Results:</title>
<p id="P4">In the F1 3xTg-AD/C3H animal model of AD, there was no detectable
reduction of brain volume over a period of 10 months of treatment, as there
was not brain atrophy in any of the placebo or treatment groups. Laquinimod
had no detectable effects on most neurobehavioral outcomes. The number or
composition of CNS intrinsic cells and mononuclear subsets isolated from the
CNS were not altered by laquinimod.</p>
</sec>
<sec id="S4">
<title>Conclusion:</title>
<p id="P5">This is the first demonstration that there are no age-associated
brain volume changes in the F1 3xTg-AD/C3H mouse model of Alzheimer’s
disease. Consequently, laquinimod had no effect on that outcome of this
study. Most secondary outcomes on the effects of laquinimod on behavior and
the number and composition of CNS-intrinsic cells and mononuclear cells
within the CNS were also negative.</p>
</sec>
</abstract>
</article-meta>
</front>
</article>
</pmc-articleset>